摘要
目的探讨胸腺肽注射液治疗小儿急性病毒性心肌炎(VMC)的疗效及对血清IL-18和TNF-α的影响。方法 80例病毒性心肌炎患儿随机分为常规疗法组(常规组)及常规疗法+胸腺肽组(胸腺肽组),治疗前、后分别测定炎性细胞因子IL-18和TNF-α,观察两组症状改善情况,并与健康儿童比较。结果胸腺肽治疗组有效率为95%,常规治疗组有效率为80%,治疗组疗效优于对照组(P<0.05)。VMC患儿治疗前急性期TNF-α和IL-18水平均明显高于恢复期与对照组,差异均有统计学意义;胸腺肽治疗组治疗后恢复期TNF-α较急性期下降,但仍高于对照组,差异无统计学意义,IL-18恢复较慢;常规治疗组治疗后恢复期TNF-α和IL-18均高于对照组,差异有统计学意义。结论加用胸腺肽注射液治疗VMC患儿,能改善临床症状和降低炎性细胞因子水平。
Objective To explore the effect of thymosin on serum interleukin - 18 and tumor necrosis factor - α in pediatric viral myocardits. Methods Eighty children diagnosed with viral myocalditis are randomly divided into two groups ： conventional therapy group and thymosin group. The serum level of interleukin - 18 and tumor necrosis factor - α were detected by enzyme linked immunosorbent assay before and 2 weeks after treatment. To observe their clinical effect and compare with normal children. Results The effective rate in thymosin group （95%） was higher than that in the conventional therapy group （80%）. The level of TNF- ot and IL- 18 in VMC children before treatment were significantly higher than those in children at remission stage and control group （ P 〈 0.05 ）. After treatment, the level of TNF - α of thymosin group was lower than those in acute stage, but higher than those in control group （ P 〉 0.05 ）. The level of TNF - α and IL - 18 of conven- tional therapy group were higher than those in control group （ P 〈 0.05 ）. Conclusion As a adjunctive therapy, thymosin can improve clinical recovery and decrease the level of inflammation cytokine.
出处
《中国医学创新》
CAS
2010年第32期3-5,共3页
Medical Innovation of China
